THE EFFECT OF SCHEDULE, PROTEIN-BINDING AND GROWTH-FACTORS ON THE ACTIVITY OF SURAMIN

被引:27
作者
LOPEZ, RL
PETERS, GJ
VANLOENEN, AC
PIZAO, PE
VANRIJSWIJK, REN
WAGSTAFF, J
PINEDO, HM
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS
[2] FREE UNIV AMSTERDAM HOSP,DEPT HOSP PHARM,1081 HV AMSTERDAM,NETHERLANDS
关键词
D O I
10.1002/ijc.2910510615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Suramin has been shown to have antiproliferative activity, either by blocking the binding of growth factors to their receptors or by inhibiting critical cellular enzymes. In 6 different cell lines from 5 tumour types (MCF-7, MCF-7/ADR(R), PC3, HT-29, UM-SCC-IIB and SW-1573/IR5OO), we studied the effect of scheduling of suramin, of FCS and of human serum albumin (HSA), of epidermal growth factor (EGF) and of the addition of growth factors in serum-free medium on the activity of suramin. The concentration of suramin which gave 50% growth inhibition (IC50) varied from 45-mu-M in SW-1573/IR500 to 153-mu-M in PC3 cells grown in medium supplemented with 5% FCS, after 6 days of continuous exposure. Exposure for more than 4 days did not enhance the sensitivity to suramin, except in PC3. At exposure to suramin for 1 day followed by 5 days recovery, high IC50 values (>0.5 mM) were observed in MCF-7 cells. In medium with 1% and 0.5% FCS these values were 3 to 8 and 14 to 26 times lower respectively. Addition of HSA increased the IC50 in PC3 and MCF-7 cells. Suramin binding to protein was dependent on the concentration of protein and of suramin. Excess of EGF in medium with different FCS concentrations did not change the IC50 values of suramin in PC3 and MCF-7 cells. Addition of EGF, fibroblast growth factor or platelet-derived growth factor in PC3 cells cultured in serum-free medium did not increase the IC50 values. Suramin was active against these 6 cell lines at clinically achievable concentrations. This activity varied depending on the cell line, exposure time and suramin concentration. The most significant factor interfering with sensitivity to suramin was the amount of protein present in the culture medium.
引用
收藏
页码:921 / 926
页数:6
相关论文
共 21 条
  • [1] ALLEY MC, 1988, CANCER RES, V48, P598
  • [2] ANTIPROLIFERATIVE EFFECTS OF SURAMIN ON ANDROGEN RESPONSIVE TUMOR-CELLS
    BERNS, EMJJ
    SCHUURMANS, ALG
    BOLT, J
    LAMB, DJ
    FOEKENS, JA
    MULDER, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) : 470 - 474
  • [3] BRODER S, 1985, LANCET, V2, P627
  • [4] SURAMIN THERAPY IN AIDS AND RELATED DISORDERS - REPORT OF THE UNITED-STATES-SURAMIN-WORKING-GROUP
    CHESON, BD
    LEVINE, AM
    MILDVAN, D
    KAPLAN, LD
    WOLFE, P
    RIOS, A
    GROOPMAN, JE
    GILL, P
    VOLBERDING, PA
    POIESZ, BJ
    GOTTLIEB, MS
    HOLDEN, H
    VOLSKY, DJ
    SILVER, SS
    HAWKINS, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (10): : 1347 - 1351
  • [5] COLLINS JM, 1986, J CLIN PHARMACOL, V26, P22
  • [6] SURAMIN - POTENT INHIBITOR OF THE REVERSE-TRANSCRIPTASE OF RNA TUMOR-VIRUSES
    DECLERCQ, E
    [J]. CANCER LETTERS, 1979, 8 (01) : 9 - 22
  • [7] EISEN V, 1973, BRIT J PHARMACOL, V49, P678, DOI 10.1111/j.1476-5381.1973.tb08544.x
  • [8] HAWKING F, 1978, ADV PHARMACOL CHEMOT, V15, P283
  • [9] SURAMIN, AN ANTI-CANCER DRUG, INHIBITS PROTEIN KINASE-C AND INDUCES DIFFERENTIATION IN NEURO-BLASTOMA CELL CLONE NB2A
    HENSEY, CE
    BOSCOBOINIK, D
    AZZI, A
    [J]. FEBS LETTERS, 1989, 258 (01): : 156 - 158
  • [10] JINDAL HK, 1990, CANCER RES, V50, P7754